Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY

Benzinga
26 Sep 2024

For the year six month period ended June 30

 Note2024



unaudited



£'000
2023



unaudited



£'000
Revenue -298
Research and development costs (2,189)(2,251)
Administrative costs (2,034)(2,291)
Loss from operations (4,223)(4,244)
Finance income3839410
Finance expense3(49)(22)
Loss before tax (3,433)(3,856)
Taxation4125288
Loss for the period attributable to the owners of the parent (3,308)(3,568)
Total comprehensive loss attributable to the owners of the parent (3,308)(3,568)
Loss per share   
Basic and diluted loss per ordinary share – pence5(0.1p)(3.6)p

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10